Keywords: Teva, Third quarter 2009 resuts, M&A speculation
Teva reports 25% sales leap for 3rd quarter 2009, boosted by Copaxone
Article | 04 November 2009
Israel-based Teva Pharmaceutical Industries, the world's largest generic drugmaker, reported higher third-quarter 2009 earnings per share of $0.89, up 16% year-on-year, boosted by ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
